Pharmaniaga

Pharmaniaga was established in 1994 as Remedi Pharmaceuticals.[1] The company was renamed as Pharmaniaga in August 1998 and is the first healthcare company in Malaysia to be listed in the Main Market of Kuala Lumpur Stock Exchange (now Bursa Malaysia).[2]

Pharmaniaga is a public limited company. Its two major shareholders are Boustead Holdings and Lembaga Tabung Angkatan Tentera (LTAT). The major owner of Boustead Holdings is itself LTAT.

Pharmaniaga's Senior Management team includes Datuk Zulkarnain Md Eusope, Group Managing Director, Zulkifli Jafar as Group Executive Director and Mohamed Iqbal Abdul Rahman as Group Deputy Managing Director. The Company's Board Members comprise YB Senator Datuk Dr. Haji Azhar Ahmad, Dr. Abdul Razak Ahmad and Sarah Azreen Abdul Samat, Datuk Lim Thean Shiang and Dr Mary Jane Cardosa as Independent Non-Executive Directors, while Izaddeen Daud is a Non-Independent Non-Executive Director.

Pharmaniaga is one of Malaysia’s largest integrated pharmaceutical groups with a firm focus on protecting the nation via providing accessible and affordable healthcare solutions, with operations in Malaysia and Indonesia.[3]

It is involved in various segments of the pharmaceutical value chain, including research and development, manufacturing of generic drugs and medical devices, logistics and distribution, sales and marketing, as well as community pharmacy.

Pharmaniaga has over 3,600 employees, and is home to more than 300 scientists, including researchers, chemists, pharmacologists, formulators, IT engineers, regulatory and clinical affairs specialists.

It has an extensive pharmaceutical logistics and distribution network in Malaysia with four warehouses equipped with pharma-grade cold rooms and delivers drugs as well as medical equipment to almost 10,000 health facilities nationwide.

With eight manufacturing plants, Pharmaniaga is capable of producing products in various forms; from oral solids, liquids and creams to small volume injectables.  Its product portfolio encompasses a diverse segment of therapeutic areas such as cardiovascular, anti-diabetic, antibiotics, antivirals, over the counter products and nutraceuticals, amongst others.  Its high tech European Union certified plant manufactures fill and finish Sinovac COVID-19 vaccine.

Its Indonesia operations include two manufacturing plants and a public listed pharmaceutical logistics and distribution company with 33 branches throughout the republic.